Inclusion Criteria:

* Age \> 18 years for AL-CA, \> 65 years for ATTR-CA, \> 65 years for controls
* Willing and able to provide consent
* Diagnosis of systemic light chain amyloidosis by standard criteria (see below) and in hematological remission (normal serum free light chain levels)

* (immunofixation of serum and urine, IgG free light chain (FLC) assay, a biopsy of fat pad/ bone marrow, or organ biopsy, followed by typing of the light chain using immunohistochemistry or immunogold assay with confirmation by Mass spectroscopy as needed) AND
* proof of cardiac involvement by AL amyloidosis
* abnormal cardiac biomarkers (Abnormal high sensitivity TnT 5th generation levels (\>9 ng/L: female, \>14 ng/L: male) or abnormal age appropriate N terminal pro-brain natriuretic peptide, NT-proBNP (abnormal values: \<50 years: \>450 pg/ml; 50-75 years:\>900 pg/ml; \>75 years: \>1800 pg/ml) or
* abnormal echocardiogram (wall thickness \> 12 mm) or
* abnormal cardiac MRI (wall thickness \> 12 mm or extracellular volume \> 0.35) OR
* Diagnosis of transthyretin cardiac amyloidosis by standard criteria

* endomyocardial biopsy followed by typing of the transthyretin amyloidosis using immunohistochemistry or immunogold assay with confirmation by Mass spectroscopy as needed
* extracardiac biopsy with typical cardiac imaging findings, or
* grade 2 or grade 3 myocardial uptake of technetium-99m pyrophosphate (PYP) if AL amyloidosis is excluded

Exclusion Criteria:

* Hemodynamic instability
* Severe claustrophobia despite use of sedatives
* Decompensated heart failure (unable to lie flat for 1 hour)
* Concomitant non-ischemic non-amyloid heart disease (valvular heart disease or dilated cardiomyopathy)
* Severe valve stenosis or regurgitation in the aortic, mitral or tricuspid valves, including prior valve replacement
* Severe pulmonary artery hypertension
* Severe lung disease
* Known obstructive epicardial coronary artery disease with stenosis \> 50% in any single territory
* Prior cardiac surgery
* Regional wall motion abnormality on echocardiogram
* Left ventricular ejection fraction \< 40%
* Pregnant state
* Documented allergy to N-13 ammonia or Definity
* Contraindications to DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension:

o Patients with known or suspected Right-to-left, bi-directional, or transient right-to-left cardiac shunts, Hypersensitivity to perflutren
* Contraindications or challenges to sonotherapy

* Severe electrolyte abnormalities
* QTc prolongation (values are greater than 450 milliseconds in males and greater than 470 milliseconds in females)
* BMI \> 35 kg/m2
* Documented intracardiac thrombus
* Atrial fibrillation not on anticoagulation
* Prior history of stroke
* Any other reason determined by the investigator that makes a subject a poor candidate for ultrasound therapy